Clinica Cayanga Medical Resources


Clinical Updates


Clinical Updates
Alzheimer's Disease
Arthritis
Benign Prostatic Hypertrophy
Chronic Lymphocytic Leukemia
Depression
Diabetes Mellitus
Dyspepsia
Erectile Dysfunction
Fatty Liver
Gallstone
Hepatitis
Hypertension
Lung Cancer
Mesothelioma
Metabolic Syndrome
Obesity
Prostate Cancer
Stroke
Tinnitus
 
Medical Library
Breaking Medical News
Clinical Tools
Dermatology
Diabetes Corner
Evidence-Based Medicine
Free Medical Books
Free Medical Journal
History Taking and Physical Examination
Medical Journal (popular)
Medical Organizations
Palm Tools
Medical Physiology (Lecture)
Medical Resources
Medical Search
Online Clinical Calculator
 
 

 

Intensive Multitheraphy in poorly controlled Type 2 Diabetes Mellitus

 

Clinical Question:
Is Intensive multitherapy for patients with poorly
controlled type 2 diabetes effective in helping patients
meet most of the goals set by a national diabetes association?

Bottom Line:

Intensive multitherapy for patients with poorly
controlled type 2 diabetes is successful in helping patients
meet most of the goals set by a national diabetes association.
However, 6 months after intensive therapy stopped and patients
returned to usual care, the benefits had vanished.

Reference:
Efficacy of intensive multitherapy for patients with type 2 diabetes mellitus: a randomized controlled trial.Menard J, Payette H, Baillargeon JP, Maheux P, Lepage S, Tessier D, Ardilouze JL.CMAJ. 2005 Nov 17; [Epub ahead of print]

Study Design:
Randomized Controlled Trial

Synopsis:
National guidelines for managing diabetes set standards for care. We sought to determine whether a 1-year intensive multitherapy program resulted in greater goal attainment than usual care among patients with poorly controlled type 2 diabetes mellitus.We identified patients with poorly controlled type 2 diabetes receiving outpatient care in the community or at our hospital. Patients 30?70 years of age with a hemoglobin A1c concentration of 8% or greater were randomly assigned to receive intensive multitherapy (n = 36) or usual care (n = 36). The average hemoglobin A1c concentration at entry was 9.1% (standard deviation [SD] 1%) in the intensive therapy group and 9.3% (SD 1%) in the usual therapy group. By 12 months, a higher proportion of patients in the intensive therapy group than in the control group had achieved Canadian Diabetes Association (CDA) goals for hemoglobin A1c concentrations (goal ? 7.0%: 35% v. 8%), diastolic blood pressure (goal < 80 mm Hg: 64% v. 37%), low-density lipoprotein cholesterol (LDL-C) levels (goal < 2.5 mmol/L: 53% v. 20%) and triglyceride levels (goal < 1.5 mmol/L: 44% v. 14%). There were no significant differences between the 2 groups in attaining the targets for fasting plasma glucose levels, systolic blood pressure or total cholesterol:highdensity lipoprotein cholesterol ratio. None of the patients reached all CDA treatment goals. By 18 months, differences in goal attainment were no longer evident between the 2 groups, except for LDL-C levels. Quality of life, as measured by a specific questionnaire, increased in both groups, with a greater increase in the intensive therapy group (13% [SD 10%] v. 6% [SD 13%], p < 0.003).

 

 

   

Home | Introduction | Scheduling a Visit| Laboratory Work Reaching Us | Map to our Office | About the Doctors

 

 

 ©2005 Clinica Cayanga. All rights reserved.